Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al.
van der Laken
C J
CJ
Lems
W F
WF
van Soesbergen
R M
RM
van der Sande
J J
JJ
Dijkmans
B A C
BA
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008875:Middle Aged; D010264:Paraplegia / Q000139:chemically induced* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept